MedTrace Logo

Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors

NCT01758146 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 412

Last updated 2020-03-04

No results posted yet for this study

Summary

To see the impact of obesity on the efficacy of adjuvant endocrine therapy with aromatase inhibitors in postmenopausal patients with early breast cancer in terms of:

i) Locoregional recurrence ii) Distant metastases iii) Disease-free survival iv) Overall survival

Conditions

Interventions

DRUG

Tamoxifen

20 mg once daily for 5 years

DRUG

Letrozole

Letroz, Femara, Letronat

Sponsors & Collaborators

  • Post Graduate Institute of Medical Education and Research, Chandigarh

    lead OTHER

Principal Investigators

  • Dr Budhi S Yadav, MD · Post Graduate Institute of Medical Education & Research, Chandigarh, India

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2020-01-31
Completion
2020-06-30

Countries

  • India

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01758146 on ClinicalTrials.gov